Literature DB >> 35079289

Assessment of the control measures of the category A diseases of Animal Health Law: Rift Valley Fever.

Søren Saxmose Nielsen, Julio Alvarez, Dominique Joseph Bicout, Paolo Calistri, Elisabetta Canali, Julian Ashley Drewe, Bruno Garin-Bastuji, José Luis Gonzales Rojas, Christian Gortázar, Mette Herskin, Virginie Michel, Miguel Ángel Miranda Chueca, Helen Clare Roberts, Barbara Padalino, Paolo Pasquali, Hans Spoolder, Karl Ståhl, Antonio Velarde Calvo, Arvo Viltrop, Christoph Winckler, Simon Gubbins, Alessandro Broglia, Inma Aznar, Yves Van der Stede.   

Abstract

EFSA received a mandate from the European Commission to assess the effectiveness of some of the control measures against diseases included in the Category A list according to Regulation (EU) 2016/429 on transmissible animal diseases ('Animal Health Law'). This opinion belongs to a series of opinions where these control measures were assessed for several diseases, with this opinion covering the assessment of control measures for Rift Valley Fever (RVF). In this opinion, EFSA and the AHAW Panel of experts review the effectiveness of: (i) clinical and laboratory sampling procedures, (ii) monitoring period and (iii) the minimum radius of the protection and surveillance zone and the minimum length of time the measures should be applied in these zones. The general methodology used for this series of opinions has been published elsewhere; nonetheless, the transmission kernels used for the assessment of the minimum radius of the protection and surveillance zones are shown. Several scenarios for which these control measures had to be assessed were designed and agreed prior to the start of the assessment. Different risk-based sampling procedures based on clinical visits and laboratory testing are assessed in case of outbreak suspicion, granting animal movements and for repopulation purposes. The length of monitoring period and minimum duration of measures to be implemented in the restricted zones as defined in the Delegated Regulation (30 days) are considered effective for the investigation and control of suspected and confirmed RVF outbreaks, as well as the size of protection and surveillance zone of 20 and 50 km, respectively, which are assessed as sufficient to contain disease transmission with at least 95% probability.
© 2022 Wiley‐VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

Entities:  

Keywords:  Disease control measures; Rift Valley Fever, RVF; monitoring period; protection zone; sampling procedures; surveillance zone

Year:  2022        PMID: 35079289      PMCID: PMC8767515          DOI: 10.2903/j.efsa.2022.7070

Source DB:  PubMed          Journal:  EFSA J        ISSN: 1831-4732


  43 in total

1.  IgG-sandwich and IgM-capture enzyme-linked immunosorbent assay for the detection of antibody to Rift Valley fever virus in domestic ruminants.

Authors:  Janusz T Paweska; Felicity J Burt; Fiona Anthony; Shirley J Smith; Antoinette A Grobbelaar; Janice E Croft; Tomas G Ksiazek; Robert Swanepoel
Journal:  J Virol Methods       Date:  2003-11       Impact factor: 2.014

2.  Development of a sheep challenge model for Rift Valley fever.

Authors:  Bonto Faburay; Natasha N Gaudreault; Qinfang Liu; A Sally Davis; Vinay Shivanna; Sun Young Sunwoo; Yuekun Lang; Igor Morozov; Mark Ruder; Barbara Drolet; D Scott McVey; Wenjun Ma; William Wilson; Juergen A Richt
Journal:  Virology       Date:  2015-12-31       Impact factor: 3.616

3.  Rift Valley fever virus and European mosquitoes: vector competence of Culex pipiens and Stegomyia albopicta (= Aedes albopictus).

Authors:  M Brustolin; S Talavera; A Nuñez; C Santamaría; R Rivas; N Pujol; M Valle; M Verdún; A Brun; N Pagès; N Busquets
Journal:  Med Vet Entomol       Date:  2017-08-07       Impact factor: 2.739

4.  Wicking assay for the rapid detection of Rift Valley fever viral antigens in mosquitoes (Diptera: Culicidae).

Authors:  M Turell; K Davé; M Mayda; Z Parker; R Coleman; S Davé; D Strickman
Journal:  J Med Entomol       Date:  2011-05       Impact factor: 2.278

5.  Number of generations, egg production, and developmental time of Culex pipiens and Culex restauns (Diptera: Culicidae) in southern Ontario.

Authors:  D J Madder; G A Surgeoner; B V Helson
Journal:  J Med Entomol       Date:  1983-05-26       Impact factor: 2.278

6.  The immunity induced in cattle and sheep by inoculation of neurotropic or pantropic Rift Valley fever viruses.

Authors:  W Coackley; A Pini; D Gosden
Journal:  Res Vet Sci       Date:  1967-10       Impact factor: 2.534

7.  Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.

Authors:  Hana M Weingartl; Charles K Nfon; Shunzhen Zhang; Peter Marszal; William C Wilson; John C Morrill; George E Bettinger; Clarence J Peters
Journal:  Vaccine       Date:  2014-01-24       Impact factor: 3.641

8.  Molecular epidemiology of Rift Valley fever virus.

Authors:  Antoinette A Grobbelaar; Jacqueline Weyer; Patricia A Leman; Alan Kemp; Janusz T Paweska; Robert Swanepoel
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

9.  Susceptibility of White-Tailed Deer to Rift Valley Fever Virus.

Authors:  William C Wilson; In Joong Kim; Jessie D Trujillo; Sun Young Sunwoo; Leela E Noronha; Kinga Urbaniak; D Scott McVey; Barbara S Drolet; Igor Morozov; Bonto Faburay; Erin E Schirtzinger; Tammy Koopman; Sabarish V Indran; Velmurugan Balaraman; Juergen A Richt
Journal:  Emerg Infect Dis       Date:  2018-09       Impact factor: 6.883

View more
  1 in total

1.  Assessment of the control measures of the Category A diseases of the Animal Health Law: prohibitions in restricted zones and risk-mitigating treatments for products of animal origin and other materials.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar Schmidt; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Karl Stahl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Kris De Clercq; Ylva Sjunnesson; Andrea Gervelmeyer; Helen Clare Roberts
Journal:  EFSA J       Date:  2022-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.